What's in Pearl Therapeutics, Inc.'s pipeline?

Pearl Therapeutics, Inc. has 29 drugs in our index: 0 marketed, 0 filed, 10 in Phase 3, 16 in Phase 2, 3 in Phase 1.

Which companies overlap with Pearl Therapeutics, Inc.'s portfolio?

Top competitors by shared drug class: Chiesi Farmaceutici S.p.A., AstraZeneca, AbbVie, Ain Shams University, Allergy & Asthma Medical Group & Research Center.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/pearl-therapeutics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Pearl Therapeutics, Inc. — Portfolio Competitive Intelligence Brief

Pearl Therapeutics, Inc. pipeline: 0 marketed, 0 filed, 10 Phase 3, 16 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 10 Phase 3 16 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
FF MDI (PT005)	FF MDI (PT005)	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor; beta-2 adrenergic receptor	Respiratory
BFF MDI (PT009)	BFF MDI (PT009)	phase 3	Triple combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist	Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor	Respiratory/Pulmonology
GFF MDI	GFF MDI	phase 3	Combination inhaled corticosteroid / long-acting beta-2 agonist / long-acting muscarinic antagonist	Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor	Respiratory / Pulmonology
Symbicort® Turbohaler® Inhalation Powder	Symbicort® Turbohaler® Inhalation Powder	phase 3	Inhaled corticosteroid/long-acting beta2-adrenergic agonist	Beta2-adrenergic receptor	Respiratory
Symbicort Turbohaler	Symbicort Turbohaler	phase 3	Corticosteroid and long-acting beta2-adrenergic receptor agonist combination	Beta2-adrenergic receptor	Respiratory
BGF MDI (PT010)	BGF MDI (PT010)	phase 3	Triple-combination inhaler (ICS/LABA/LAMA)	Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor	Respiratory/Pulmonology
GP MDI (PT001)	GP MDI (PT001)	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor; beta-2 adrenergic receptor	Respiratory/Pulmonology
GP MDI	GP MDI	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist combination	Beta-2 adrenergic receptor and glucocorticoid receptor	Respiratory/Pulmonology
FF MDI	FF MDI	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor; Beta-2 adrenergic receptor	Respiratory/Pulmonology
GFF MDI (PT 003)	GFF MDI (PT 003)	phase 3	Long-acting beta-2 agonist / Long-acting muscarinic antagonist combination (LABA/LAMA)	Beta-2 adrenergic receptor; Muscarinic M3 receptor	Respiratory / Pulmonology

Therapeutic area mix

Respiratory · 8
Respiratory/Pulmonology · 6
Respiratory / Pulmonology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Chiesi Farmaceutici S.p.A. · 3 shared drug classes
AstraZeneca · 2 shared drug classes
AbbVie · 1 shared drug class
Ain Shams University · 1 shared drug class
Allergy & Asthma Medical Group & Research Center · 1 shared drug class
Allergy and Asthma Center of El Paso · 1 shared drug class
Astellas Pharma Inc · 1 shared drug class
Aclaris Therapeutics, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Pearl Therapeutics, Inc.:

Cite this brief

Drug Landscape (2026). Pearl Therapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pearl-therapeutics-inc. Accessed 2026-05-16.